drugset / Trial / NCT03929211
CPI-613 and Hydroxychloroquine for Patients With High Risk Myelodysplastic Syndrome
NaSingle-groupOpen-labelTreatment
Summary
This is a phase 1/2 study of the combination of CPI-613 and hydroxychloroquine for the treatment of high risk myelodysplastic syndrome patients who have failed a hypomethylating agent.
Timeline
- Start
- 2021-05
- Primary completion
- 2022-09
- Completion
- 2027-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CPI-613 | Small molecule | 2000 mg/m2 | Intravenous |
| Subject | Hydroxychloroquine | Small molecule | 600 mg | Oral |
| Subject | Hydroxychloroquine | Small molecule | 1200 mg | Oral |